<DOC>
	<DOCNO>NCT00736164</DOCNO>
	<brief_summary>RATIONALE : Selenomethionine may slow growth prostate cancer . Giving selenomethionine surgery internal radiation therapy may effective treatment prostate cancer . PURPOSE : This randomized phase II trial study well selenomethionine work treat patient undergo surgery internal radiation therapy stage I stage II prostate cancer .</brief_summary>
	<brief_title>Selenomethionine Treating Patients Undergoing Surgery Internal Radiation Therapy Stage I Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To investigate down-regulation androgen receptor use tissue sample patient stage I II prostate cancer treat selenomethionine 8-9 week prior undergo prostatectomy brachytherapy . Secondary - To evaluate regulation number gene regulate androgen receptor ( i.e. , prostate-specific antigen , kallikrein 2 , cell division cycle 6 , dehydrocholesterol reductase 24 ) use tissue sample patient . - To evaluate down-regulation haptic nuclear factor 3-alpha use tissue sample patient . - To evaluate whether thiol methyltransferase phenotype modifies prostatic response short-term selenomethionine supplementation patient . Tertiary - To use quantitative nuclear morphometry index cellular abnormality tissue sample measure nuclear texture ( e.g. , total optical density , nuclear area , mean nuclear density , optical heterogeneity ) . OUTLINE : Patients stratify accord plan treatment ( brachytherapy v prostatectomy ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral selenomethionine daily 8-9 week . Patients undergo prostatectomy brachytherapy . - Arm II : Patients receive oral placebo daily 8-9 week . Patients undergo prostatectomy brachytherapy . Blood sample collect baseline day prostatectomy brachytherapy . Samples analyze selenium accumulation atomic absorption spectrophotometry . Additional blood sample store future analysis alpha tocopherol , lycopene , vitamin level , well oxidative stress biomarkers . Selenium accumulation also evaluate toenail sample baseline assess long-term selenium status . Prostate tissue sample obtain prostatectomy brachytherapy analyze RNA expression selenium-linked biomarkers ( e.g. , androgen receptor , prostate-specific antigen , kallikrein 2 , cell division cycle 6 , dehydrocholesterol reductase 24 , haptic nuclear factor 3 alpha ) quantitative reverse transcription ( RT ) -PCR . Biomarker expression compare prostatectomy brachytherapy specimen .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Diagnosed sextant great biopsy Clinical stage T1aT2c disease Gleason score &lt; 8 Prostatespecific antigen &lt; 20.0 ng/mL Scheduled undergo prostatectomy brachytherapy PATIENT CHARACTERISTICS : Life expectancy &gt; 5 year No prior malignancy except nonmelanoma skin cancer Willing take selenomethionine placebo 89 week immediately prior undergo prostatectomy brachytherapy PRIOR CONCURRENT THERAPY : No prior hormonal therapy radiotherapy More 30 day since prior concurrent participation clinical trial involve medical , surgical , nutritional , lifestyle intervention ( e.g. , dietary modification exercise ) No concurrent dietary supplementation selenium dose &gt; 60 mcg/day , include multivitamin supplement No concurrent hormonal therapy , include 5alpha reductase inhibitor ( e.g. , finasteride dutasteride ) ; antiandrogens ( e.g. , bicalutamide , flutamide , ketoconazole ) ; luteinizing hormonereleasing hormone agonist ( e.g. , leuprolide acetate , goserelin acetate , abarelix )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>